Preliminary Efficacy of OMO-1 as Monotherapy and Combined With EGFR TKI
NSCLC, Tumor, EGFR-positive stage
DISEASE PROGRESSION, TUMOR, DISEASE, BEST, NSCLC
In the METex14 NSCLC expansion cohort, 10 patients were treated with OMO-1 monotherapy. Nine patients had at least one response evaluation by imaging. The majority of the patients had stable disease as the best response (8/9 patients) (Response to OMO-1 of MET exon 14 mutated NSCLC cohort. One patient was treated in Module 2 (combination with EGFR TKI); a 55-year-old female, with an EGFR-positive stage 4 NSCLC who had progressed on gefitinib. Tumor biopsy at progression showed an acquired MET amplification for which the patient was included in Module 2. Patient was treated with 200 mg BID of OMO-1 in combination with gefinitib (EGFR TKI). OMO-1 was interrupted due to serum Cystatin C increase of >1.5 fold from baseline, considered related to OMO-1. OMO-1 was restarted at one dose level lower (100 mg BID). Best response by local assessment was stable disease and best response by central assessment was partial response. Treatment was discontinued in week 23 due to disease progression.